KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash & Equivalents (2017 - 2025)

Guardant Health's Cash & Equivalents history spans 9 years, with the latest figure at $378.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 28.04% year-over-year to $378.2 million; the TTM value through Dec 2025 reached $378.2 million, down 28.04%, while the annual FY2025 figure was $378.2 million, 28.04% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $378.2 million at Guardant Health, down from $580.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.1 billion in Q4 2023 and bottomed at $141.6 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $576.8 million (2022), against an average of $583.3 million.
  • The largest annual shift saw Cash & Equivalents crashed 80.98% in 2022 before it soared 700.25% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $492.2 million in 2021, then crashed by 71.22% to $141.6 million in 2022, then surged by 700.25% to $1.1 billion in 2023, then plummeted by 53.64% to $525.5 million in 2024, then dropped by 28.04% to $378.2 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Cash & Equivalents are $378.2 million (Q4 2025), $580.0 million (Q3 2025), and $629.1 million (Q2 2025).